# Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

> **NCT02520284** · PHASE2,PHASE3 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 165 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **BIOLOGICAL:** Andecaliximab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02520284
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09
- **Primary completion:** 2016-09
- **Final completion:** 2016-11
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2019-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02520284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02520284, "Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02520284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*